Item 2.02 Results of Operations and Financial Condition.

On January 11, 2021, Heron Therapeutics, Inc. (the "Company") issued a press release announcing, among other things, certain of its financial results for the three and twelve months ended December 31, 2020 (the "Press Release"). A copy of the Press Release is furnished herewith as Exhibit 99.1.

This Item 2.02 and the Press Release attached hereto as Exhibit 99.1 are being furnished to the Securities and Exchange Commission.

Item 7.01 Regulation FD Disclosure.

Press Release.

On January 11, 2021, the Company issued the Press Release providing, among other things, a general update on corporate progress, as described in the Press Release.

Corporate Presentation.

A copy of presentation materials describing the business of the Company, all or a part of which may be used by the Company in investor or scientific presentations from time to time, is furnished herewith as Exhibit 99.2 (the "Corporate Presentation"). The Corporate Presentation has also been posted on the Company's website at www.herontx.com. The Company does not undertake any obligation to update the Corporate Presentation.

This Item 7.01, the Press Release and the Corporate Presentation are being furnished to the Securities and Exchange Commission.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.



Exhibit No.   Description

99.1            Press Release, dated January 11, 2021
99.2            Corporate Presentation, dated January 11, 2021
104           Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses